Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study

BACKGROUND: Typhoid fever is a major cause of morbidity and mortality in low-income and middle-income countries. In 2017, WHO recommended the programmatic use of typhoid Vi-conjugate vaccine (TCV) in endemic settings, and Gavi, The Vaccine Alliance, has pledged support for vaccine introduction in th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Infect Dis
Autors principals: Bilcke, Joke, Antillón, Marina, Pieters, Zoë, Kuylen, Elise, Abboud, Linda, Neuzil, Kathleen M, Pollard, Andrew J, Paltiel, A David, Pitzer, Virginia E
Format: Artigo
Idioma:Inglês
Publicat: Elsevier Science ;, The Lancet Pub. Group 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6595249/
https://ncbi.nlm.nih.gov/pubmed/31130329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(18)30804-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars